Trial Profile
Phase II trial of S-1+oxaliplatin+Cetuximab as first-line treatment in patients with kras-wild type unresectable advanced colorectal cancer - KODK 9 -
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 May 2016
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms KODK9
- 26 Sep 2012 New trial record